Home
Search
Study Topics
Glossary
|
|
|
|
|
|
Sponsored by: |
MIGENIX Inc. |
---|---|
Information provided by: | MIGENIX Inc. |
ClinicalTrials.gov Identifier: | NCT00211497 |
This is a Phase II, randomized, vehicle-controlled, double-blind, multi center study to evaluate the efficacy and safety of topically applied MBI 226 1.25% and 2.5% Acne Solutions as anti-acne preparations in human subjects with facial acne vulgaris.
Condition | Intervention | Phase |
---|---|---|
Acne Vulgaris Acne Propionibacterium Acnes |
Drug: MBI 226 Acne Solutions |
Phase II |
Study Type: | Interventional |
Study Design: | Treatment, Randomized, Double-Blind, Placebo Control, Parallel Assignment, Safety/Efficacy Study |
Official Title: | A Phase II, Randomized, Vehicle-Controlled, Double-Blind, Multi-Center Study to Evaluate Safety and Efficacy of MBI 226 1.25% and 2.5% Acne Solutions Applied Topically for 12 Weeks to Subjects With Acne Vulgaris |
Estimated Enrollment: | 255 |
Study Start Date: | January 2003 |
Estimated Study Completion Date: | September 2003 |
Ages Eligible for Study: | 12 Years and older |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion Criteria:
Study ID Numbers: | A99005 |
Study First Received: | September 13, 2005 |
Last Updated: | September 13, 2005 |
ClinicalTrials.gov Identifier: | NCT00211497 |
Health Authority: | United States: Food and Drug Administration |
acne vulgaris acne Propionibacterium acnes topical |
inflammatory non-inflammatory lesion counts lesions |
Exanthema Facial Dermatoses Facies |
Skin Diseases Sebaceous Gland Diseases Acne Vulgaris |
Acneiform Eruptions |